Cyrus Taraporevala Elected to Pfizer’s Board of Directors
Pfizer announced the election of Cyrus Taraporevala to its Board of Directors, effective immediately. At 57, Mr. Taraporevala will join Pfizer’s Audit and Compensation Committees. He brings extensive experience from his tenure as President and CEO at State Street Global Advisors (2017-2022) and prior roles at Fidelity, BNY Mellon, Legg Mason, Citigroup, and McKinsey & Company. He currently serves on the boards of Shell and Bridgepoint Group. Pfizer CEO Albert Bourla praised Mr. Taraporevala's investment management and global operations expertise, stating it will benefit Pfizer and its shareholders. Mr. Taraporevala holds a Bachelor of Commerce from the University of Bombay and an MBA from Cornell University.
- Cyrus Taraporevala's extensive experience in investment management and financial markets is expected to strengthen Pfizer's Board.
- His leadership roles at major financial institutions like State Street, Fidelity, and BNY Mellon bring valuable insights into global operations and financial strategies.
- Potential concerns regarding continuity and experience gaps as Mr. Taraporevala transitions from retirement back into active corporate leadership.
Mr. Taraporevala served as President and Chief Executive Officer at State Street Global Advisors from 2017 until his retirement in 2022. Prior to joining State Street, he held numerous leadership roles in asset management, including at Fidelity, BNY Mellon, Legg Mason, and Citigroup. Earlier in his career, Mr. Taraporevala was a partner at McKinsey & Company, based in
He serves on the boards of directors of Shell plc and Bridgepoint Group plc.
Mr. Taraporevala received a Bachelor of Commerce in Financial Accounting from Sydenham College, University of
“We are pleased to welcome Cyrus Taraporevala to Pfizer’s Board of Directors,” stated Albert Bourla, Pfizer Chairman and Chief Executive Officer. “He brings vast experience in investment management, financial markets plus leadership and global operations more broadly that will be an asset to Pfizer and enable our shareholders to continue to benefit from a Board representing a balance of experience, competencies and perspectives.”
About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on X at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
Category: Corporate
View source version on businesswire.com: https://www.businesswire.com/news/home/20240701406556/en/
Media Contact: PfizerMediaRelations@Pfizer.com
+1 (212) 733-1226
Investor Contact: IR@Pfizer.com
+1 (212) 733-4848
Source: Pfizer Inc.
FAQ
Who is Cyrus Taraporevala and what is his new role at Pfizer?
What is Cyrus Taraporevala's background?
How might Cyrus Taraporevala's appointment impact Pfizer shareholders?
What educational qualifications does Cyrus Taraporevala have?
What other boards does Cyrus Taraporevala serve on?
